A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report

A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report

Abstract Background Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class of agents. The current opinion is that in case of severe liver toxicity pazopanib should be interrupted and...

Full description

Bibliographic Details
Main Authors: Arie J. Verschoor, Fabiënne A. R. M. Warmerdam, Tjalling Bosse, Judith V. M. G. Bovée, Hans Gelderblom
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
Pazopanib
Endometrial stromal sarcoma
Liver function
Adverse events
Response
Online Access:http://link.springer.com/article/10.1186/s12885-018-3999-0

Internet

http://link.springer.com/article/10.1186/s12885-018-3999-0

Similar Items